Remdesivir Races Through EU Review
Gilead Sciences’ remdesivir could get the nod from the European Medicines Agency this week as a treatment for COVID-19, paving the way for swift EU approval.
You may also be interested in...
A number of drug companies are set to learn the fate of their marketing authorization applications in the EU this week.
The much-anticipated EU filing for Gilead’s COVID-19 treatment is being reviewed quickly by the European Medicines Agency.